Oystein F. Saebo - Chief Technology Officer, Director & Founder
Oystein brings deep computer science expertise to Pathogenomix and is a key inventor in creating
and developing Pathogenomix's RipSeq product portfolio. He developed the Company's patented
algorithms, large user base cloud solutions, and web-server deployment through server-side
parallel processing, and is considered by many to be a leading authority in his
line of work. Oystein is a co-founder of Pathogenomix. He has extensive international experience
as a Principal Consultant and Systems Architect, and has over 20 years of algorithm
design and development experience, working with Life Technologies / Thermo Fisher, Microsoft, Motorola, Grant Thornton and others.
Oyvind Kommedal, MD, PhD - Medical advisor
Oyvind is an internationally-recognized microbiologist whose unique insights about
the intersection of medicine, technology, and business have guided Pathogenomix's vision
and product development. Oyvind is a co-founder of Pathogenomix and one of the key
inventors of the RipSeq. As a medical doctor specializing in infectious diseases Oyvind has gathered
over 10 years of experience in routine diagnostics and research. He is currently
leading a brain abscess study using Sanger and Next Generation Sequencing combined
with Pathogenomix RipSeq software. He has authored or co-authored articles in more than 10 scientific publications
(including Journal of Clinical Microbiology and the Journal of Medical Microbiology) utilizing RipSeq.
May Kristin Roen - COO and Co-founder
May brings her extensive experience in scaling early-stage companies to Pathogenomix's management.
As a survivor of a bacterial infection that nearly killed her in 1999, her passion for Pathogenomix's
mission is personal as well as professional.
May has an Executive MBA in Finance Management Control as well as a Bachelor of Engineering and Master of
Science in Landscape Architecture. Specializing in finance, management, HR and business development.
She relocated to the US in 2011 with Isentio (now Pathogenomix) and worked for 3 years as a finance consultant
and ran finance operations for more than 43 global companies. The last years she has served as CFO/VP
Finance for several BayArea tech companies. She also serves on several boards for both nonprofit and for-profit
companies and organizations.
Marianne Nome - MD, Business Developer
Marianne has a unique background with clinical work in emergency medicine and orthopedic
surgery to research in cancer genetics, onco-immunology, genomics and
bioinformatics with a focus on breast cancer and the effects of immune
responses, inflammation and metabolic processes. She has written several
publications as well as having hands on lab experience from working in a
sequencing lab at Mount Sinai hospital in NY in relation to her research.
Marianne also have extensive experience working with precision medicine in oncology at
Rutgers University, served on the molecular tumor board at Cancer Institute of
New Jersey and been a medical advisor and consultant to several med-tech and biotech companies.
Chris Risley - Chairman
Chris is an early stage investor who has led 8 Venture Capital backed companies
resulting in one IPO, five acquired by Public Companies, and two acquired by Private
Companies. Acquirers included: IBM, F5, Tibco, and Symantec. In addition, he spent
10 years as an Operating Partner at Bessemer Venture Partners. Prior to joining
the Software Industry he spent 2 years as Advisor to the Chairman of British Aerospace.
He holds a BA Magna Cum Laude from Cornell University and did the PMD program at
Harvard Graduate School of Business.
Ivan O'Sullivan - Director
Ivan is a software investor with a focus on SaaS services. He has more than 20 years
of sales, marketing, and business development experience. Most recently Ivan was
an executive at Defense.Net, acquired by F5 Networks; Digital Reef, acquired by
Transperfect and Metalogix, acquired by Permira. Prior to Metalogix, he was SVP
at StreamBase Systems (acquired by Tibco), Earlier in his career Ivan served as
president of Elron Software (acquired by Zix Corp.) and North American president
of Clearswift. He also held executive roles at Signiant (secure file sharing) and
ON Technology Corp., (acquired by Symantec). Ivan holds a B.A. First Class Honors
in business studies from London's Thames Polytechnic.